BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that BioTelemetry Research, their leading global imaging and cardiac core lab, and AMRA, the international leader in body composition analysis, have formed an exclusive alliance for non-alcoholic fatty […]Oct 25, 2017
The Research Division of BioTelemetry
BioTelemetry Research is an industry leader in clinical trials testing services, monitoring, data, and scientific consulting. Our comprehensive offerings provide global clients with world-leading technology, data management, and consulting services, streamlining the clinical trials process, and ensuring optimal research performance.
Every day, BioTelemetry Research’s global clinical trials services team meets the demands of Phase I–IV studies for the world’s largest pharmaceutical organizations, specialty pharmaceutical firms, emerging biotechnology companies, and medical device manufacturers. Providing a full range of centralized clinical trials testing modalities for both safety and endpoint evaluation, our core offerings include:
Comprehensive Testing Services for Clinical Trials
Today as BioTelemetry Research, we are a member of the world’s largest cardiac data network — processing over 2 billion heartbeats a day, while supporting more than 20,000 sites and 30,000 devices monthly, as well as monitoring over 600,000 patients and subjects a year. In addition to industry-leading global cardiovascular monitoring, we provide advanced imaging services for oncology, cardiovascular, metabolic diseases, neurologic, musculoskeletal imaging.
San Diego, CA
Wearable technologies are on the verge of changing the landscape of how patients interact with doctors and life sciences companies. Join BioTelemetry Research experts to learn more about the innovations in mHealth.Dec 4-5, 2017
Publications / White Papers
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatisis (NASH) are emerging as the most prevalent causes of liver disease in Western countries…
Key Takeaways from the New CSRC/FDA Meeting on Cardiac Safety and Cardiovascular Safety Issues in Oncology Drug Development Nov 1, 2017
Join Polina Voloshko, MD, Chief Medical Officer and Daniel Goodman, MD, Vice President and Medical Director, to learn about the updates from the new CSRC/FDA meeting on cardiac safety and cardiovascular safety issues in oncology drug development to optimize your clinical trial.